Arkolith/Insider Trading/KNSA/Form 4

Tessari Eben

CHIEF OPERATING OFFICERKiniksa Pharmaceuticals International, plc (KNSA) · full profile →Form 4 · filed Dec 1, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$9K
Net Open-Market Flow
-$9K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 26, 2025Sell(S)200$42.89$9K23K
Nov 26, 2025Option exercise(M)200$22.89$5K23K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 26, 2025Option exercise(M)200—$047K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001867899-25-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML